Lyell Immunopharma (NASDAQ:LYEL) Issues Earnings Results, Misses Expectations By $0.52 EPS

Lyell Immunopharma (NASDAQ:LYEL) announced its quarterly earnings data on Tuesday. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52), Zacks reports. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%.

Lyell Immunopharma Trading Down 2.3 %

Shares of NASDAQ LYEL traded down $0.02 during midday trading on Tuesday, reaching $0.67. 482,506 shares of the stock were exchanged, compared to its average volume of 1,061,552. The stock has a 50 day moving average price of $0.63 and a 200-day moving average price of $0.94. The company has a market capitalization of $194.49 million, a P/E ratio of -0.84 and a beta of -0.41. Lyell Immunopharma has a 52-week low of $0.51 and a 52-week high of $3.15.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, November 12th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.